KLOW 80 — what is actually in the vial

A market name, not a formulation

KLOW is a name the research-supply market settled on, not one any pharmacopoeia or registry defines. That distinction matters more than it sounds: a CAS number guarantees a specific molecule, and an INN guarantees a specific drug substance, but a blend name guarantees nothing. Two vials labelled KLOW from different suppliers can carry different compounds in different proportions, and neither supplier is doing anything irregular.

The number is the only arithmetic part of the name. 80 is the combined mass in milligrams of everything in the vial — not a potency rating, not a purity figure, and not a statement about any individual component. An 80 mg blend is not stronger than a 10 mg single compound; it contains more total material spread across more molecules.

The four components

The molecular weights span more than a factor of fourteen, from KPV at 342.43 g/mol to TB-500 at 4963.44. That spread is the single most useful thing to understand about any blend, because it means equal masses are wildly unequal molecule counts. A milligram of KPV is roughly fourteen times as many molecules as a milligram of TB-500.

What the fourth component changes analytically

Adding KPV changes the analysis more than adding ten milligrams suggests. At three residues it sits at the lower edge of what the standard identity toolkit resolves comfortably: very short peptides give sparse fragmentation patterns under mass spectrometry and elute early on reversed-phase HPLC, sometimes near the solvent front where the baseline is least clean.

So a four-component certificate is not simply a three-component certificate with one more row. The smallest component is also the hardest one to characterise, and a blend certificate that reports a single purity figure has not established that KPV is present at all, let alone in what proportion.

Why the copper matters across the whole vial

GHK-Cu is not a plain peptide but a tripeptide bound to a copper(II) ion, and the metal is part of the compound rather than an additive or contaminant. That gives the blend two properties it would not otherwise have. It is coloured — copper(II) absorbs in the visible range, which is why GHK-Cu material is blue rather than white. And it is pH-sensitive in a way peptides are not: under sufficiently acidic conditions the copper dissociates, leaving free peptide and free copper rather than the intended complex.

Copper ions also catalyse oxidation, and TB-500 carries a methionine — the most oxidation-prone of the twenty amino acids. Having an oxidation catalyst and an oxidation-prone residue in the same vial is worth accounting for in storage, and it is a consideration that exists only because these compounds share a container.

Reading a KLOW certificate

• ◆Check that four distinct masses are reported, not one blended figure. The components differ enough — 342, 403, 1420 and 4963 g/mol — that mass spectrometry can separate them unambiguously.
• ◆Confirm GHK-Cu's mass corresponds to the copper-containing complex rather than the bare tripeptide. The metal is the difference between the two figures.
• ◆Treat a single purity percentage as answering a narrower question than it appears to. Area percent across a chromatogram with four intended compounds does not establish which peak is which.
• ◆Look for KPV specifically. It is the component most likely to be under-reported, because it is the hardest to resolve.
• ◆Match the lot number on the certificate to the one on your vial. Every published certificate is in the COA library.

Evidence status

Each constituent has its own preclinical literature and none is approved for human use in the United States. No controlled study has examined these four compounds administered together, so the blend carries each component's uncertainty plus untested interaction between them — it does not carry more evidence than its parts, and a four-component blend carries more untested interactions than a three-component one. BPC-157 was additionally placed in the FDA's Category 2 of bulk drug substances, a regulatory finding of public record.